$KYMR · Kymera Therapeutics, Inc.
Kymera Therapeutics reported Q3 2026 financial results alongside positive Phase 1 data for KT-579 (IRF5 degrader) in healthy volunteers. KT-579 demonstrated ≥90% median IRF5 degradation, robust suppression of disease-relevant biomarkers, and a placebo-comparable safety profile. The company also confirmed the last patient completed the week 16 visit in the KT-621 (STAT6) BROADEN2 Phase 2b AD trial, with topline data expected by year-end 2026. Q3 net loss widened to $132.0M from $82.2M YoY as R&D expenses nearly doubled to $128.5M. Cash stands at $1.6B with runway into 2029.
- KT-579 Phase 1 healthy volunteer trial showed ≥90% median IRF5 degradation across multiple dose levels with a safety profile comparable to placebo.
- KT-579 demonstrated 88% inhibition of TNFα, 87% of IL-12/23p40, 94% of IL-1β, and 98% of IFNβ at Day 14.
- Last patient completed the week 16 visit in the KT-621 BROADEN2 Phase 2b AD trial; topline data expected by year-end 2026.
- Q3 2026 net loss was $132.0M ($1.32/share) vs $82.2M ($0.94/share) in Q3 2025, driven by R&D spend doubling to $128.5M.
- Cash position of $1.6B as of September 30, 2026, with runway into 2029.
Extended-hours trading shows KYMR at $123.99, up +1.21% vs the regular close of $122.51, reflecting positive reception to the KT-579 Phase 1 data and the KT-621 catalyst timeline. The $10.08B market cap suggests the market is already pricing in significant pipeline optionality.
Kymera delivered positive first-in-human data for its second major immunology degrader (KT-579) while teeing up a binary catalyst for its lead STAT6 program (KT-621) within two months — a rare dual-inflection setup for a $10B biotech.
Kymera is advancing oral small-molecule degraders against validated immunology targets (STAT6, IRF5), competing with injectable biologics like Dupixent. Positive KT-621 Phase 2b data would position it as a first oral alternative in the $20B+ Type 2 inflammatory disease market.
KT-579 Phase 1 healthy volunteer data may not predict efficacy in lupus patients; the LUMORA Phase 1b trial won't start until early 2027. KT-621 BROADEN2 topline data is a binary event — failure would materially impair the lead program and the STAT6 thesis.